Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AFTAB AHMAD

Allopathic & Osteopathic Physicians Family Medicine

NPI
1578625505
CMS profile
161805
Location
HUMBLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$235.20

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $235.20 8

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AFTAB AHMAD

NPI 1578625505 · CMS profile ID 161805

Allopathic & Osteopathic Physicians / Family Medicine

HUMBLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578625505?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AFTAB AHMAD, NPI 1578625505, CMS profile ID 161805. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578625505?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AFTAB AHMAD, NPI 1578625505, CMS profile ID 161805. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578625505?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AFTAB AHMAD, NPI 1578625505, CMS profile ID 161805, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578625505?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $235.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $26.7612/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852396229 CMS
AstraZeneca Pharmaceuticals LP $14.7710/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834341069 CMS
AstraZeneca Pharmaceuticals LP $119.0509/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834324445 CMS
Novo Nordisk Inc $17.4309/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811014051 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4509/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763569034 CMS
AstraZeneca Pharmaceuticals LP $8.1507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834350111 CMS
Novo Nordisk Inc $23.1007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810822575 CMS
Lilly USA, LLC $11.4903/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818919865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75.86 5
PY2020 $144.46 9
PY2021 $235.20 8
PY2022 $255.65 15
PY2023 $563.85 29
PY2024 $507.43 21
PY2025 $499.00 25

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $18,049.62 5
PY2020 Principal investigator $36,610.70 31
PY2019 Recipient $1,202.48 10
PY2019 Principal investigator $237,240.39 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $6,320.24 12/31/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122757
Principal investigator 1 AbbVie, Inc. $11,500.00 12/24/2019 Non-covered Recipient Entity
Research Trials Worldwide, LLC
M16-100 No dispute reported 06/30/2026 647611279
Principal investigator 1 Novo Nordisk AS $4,213.12 12/19/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444887
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670115483
Principal investigator 1 Allergan Inc. $3,345.90 12/13/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110673
Principal investigator 1 Novo Nordisk AS $2,880.00 12/05/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444885
Principal investigator 1 Allergan Inc. $375.00 12/01/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670104841
Principal investigator 1 Allergan Inc. $3,082.75 11/13/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096831
Principal investigator 1 Allergan Inc. $327.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095515
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095589
Principal investigator 1 Allergan Inc. $4,200.00 11/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095239
Principal investigator 1 Novo Nordisk AS $9.99 11/06/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706413
Principal investigator 1 Novo Nordisk AS $22.50 11/06/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706415
Principal investigator 1 Novo Nordisk AS $5,222.53 10/29/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444871
Principal investigator 1 Novo Nordisk AS $23.06 10/24/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706411
Principal investigator 1 Novo Nordisk AS $46.12 10/16/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706409
Principal investigator 1 Allergan Inc. $4,460.25 10/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085697
Principal investigator 1 Novo Nordisk AS $2.65 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706391
Principal investigator 1 Novo Nordisk AS $10.60 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706393
Principal investigator 1 Novo Nordisk AS $5.69 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706395
Principal investigator 1 Novo Nordisk AS $4.99 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706397
Principal investigator 1 Novo Nordisk AS $9.00 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706399
Principal investigator 1 Novo Nordisk AS $30.00 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706401
Principal investigator 1 Novo Nordisk AS $3.25 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706403
Principal investigator 1 Novo Nordisk AS $4.90 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706405
Principal investigator 1 Novo Nordisk AS $72.00 10/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706407
Principal investigator 1 Novo Nordisk AS $10,494.58 09/26/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444881
Principal investigator 1 Novo Nordisk AS $30.00 09/24/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706389
Principal investigator 1 Allergan Inc. $3,105.55 09/18/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076817
Recipient GlaxoSmithKline, LLC. $213.14 09/10/2019 Covered Recipient Physician A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 709081463
Recipient GlaxoSmithKline, LLC. $96.47 09/10/2019 Covered Recipient Physician A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 709081487
Recipient GlaxoSmithKline, LLC. $30.86 09/10/2019 Covered Recipient Physician A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 709082751
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670072946
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071833
Principal investigator 1 Novo Nordisk AS $6.10 09/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706379
Principal investigator 1 Novo Nordisk AS $2.16 09/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706381
Principal investigator 1 Novo Nordisk AS $5.69 09/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706383
Principal investigator 1 Novo Nordisk AS $4.99 09/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706385
Principal investigator 1 Novo Nordisk AS $6.50 09/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706387
Principal investigator 1 Novo Nordisk AS $2,197.00 08/30/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444877
Principal investigator 1 Novo Nordisk AS $325.00 08/30/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444879
Principal investigator 1 Novo Nordisk AS $9.99 08/28/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706375
Principal investigator 1 Novo Nordisk AS $23.06 08/28/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706377
Principal investigator 1 Novo Nordisk AS $19.98 08/21/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706371
Principal investigator 1 Novo Nordisk AS $46.12 08/21/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706373
Principal investigator 1 Allergan Inc. $3,022.90 08/14/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065497
Principal investigator 1 Novo Nordisk AS $2.65 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706357
Principal investigator 1 Novo Nordisk AS $9.00 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706359
Principal investigator 1 Novo Nordisk AS $30.00 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706361
Principal investigator 1 Novo Nordisk AS $4.90 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706363
Principal investigator 1 Novo Nordisk AS $4.80 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706365
Principal investigator 1 Novo Nordisk AS $4.80 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706367
Principal investigator 1 Novo Nordisk AS $72.00 08/08/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706369
Principal investigator 1 Novo Nordisk AS $3,000.00 07/31/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444873
Principal investigator 1 Novo Nordisk AS $1,000.00 07/31/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN9535-4506 No dispute reported 06/30/2026 692444875
Principal investigator 1 Novo Nordisk AS $78,682.97 07/30/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444883
Principal investigator 1 Novo Nordisk AS $144.09 07/18/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706355
Principal investigator 1 Allergan Inc. $4,460.25 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057127
Principal investigator 1 Novo Nordisk AS $5.30 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706341
Principal investigator 1 Novo Nordisk AS $49.98 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706343
Principal investigator 1 Novo Nordisk AS $9.00 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706345
Principal investigator 1 Novo Nordisk AS $60.00 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706347
Principal investigator 1 Novo Nordisk AS $6.50 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706349
Principal investigator 1 Novo Nordisk AS $9.80 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706351
Principal investigator 1 Novo Nordisk AS $36.00 07/15/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706353
Principal investigator 1 Allergan Inc. $14,000.00 06/25/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670053753
Principal investigator 1 Novo Nordisk AS $250.00 06/25/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444869
Principal investigator 1 Novo Nordisk AS $1.14 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706321
Principal investigator 1 Novo Nordisk AS $11.38 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706323
Principal investigator 1 Novo Nordisk AS $9.98 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706325
Principal investigator 1 Novo Nordisk AS $5.30 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706327
Principal investigator 1 Novo Nordisk AS $49.98 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706329
Principal investigator 1 Novo Nordisk AS $9.00 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706331
Principal investigator 1 Novo Nordisk AS $60.00 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706333
Principal investigator 1 Novo Nordisk AS $6.50 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706335
Principal investigator 1 Novo Nordisk AS $9.80 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706337
Principal investigator 1 Novo Nordisk AS $36.00 06/12/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706339
Principal investigator 1 Novo Nordisk AS $63.52 06/10/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706317
Principal investigator 1 Allergan Inc. $6,311.80 05/28/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048177
Principal investigator 1 Allergan Inc. $289.00 05/28/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670049224
Principal investigator 1 Allergan Inc. $490.00 05/20/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670046657
Principal investigator 1 Novo Nordisk AS $75.00 05/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE, LLC
NN9535-4506 No dispute reported 06/30/2026 706706319
Recipient AbbVie, Inc. $38.69 05/03/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627723
Principal investigator 1 Allergan Inc. $10,608.65 04/25/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041309
Principal investigator 1 Allergan Inc. $2,400.00 04/11/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670037507
Recipient AbbVie, Inc. $18.75 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627727
Recipient AbbVie, Inc. $18.86 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627729
Recipient AbbVie, Inc. $487.02 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627731
Recipient AbbVie, Inc. $58.57 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627733
Recipient AbbVie, Inc. $36.06 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627735
Recipient AbbVie, Inc. $204.06 04/04/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647627725
Principal investigator 1 Allergan Inc. $375.00 04/04/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670035905
Principal investigator 1 Allergan Inc. $500.00 04/04/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670036081
Principal investigator 1 Allergan Inc. $15,496.40 03/26/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033369
Principal investigator 1 Kowa Research Institute, Inc. $500.00 03/11/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
K-877-302 No dispute reported 06/30/2026 629130305
Principal investigator 1 Allergan Inc. $375.00 03/05/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028741
Principal investigator 1 Allergan Inc. $4,136.30 02/28/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028045
Principal investigator 1 Allergan Inc. $375.00 02/21/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670026449
Principal investigator 1 Allergan Inc. $825.00 02/21/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670026607
Principal investigator 1 Novo Nordisk AS $999.12 02/21/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444867
Principal investigator 1 Novo Nordisk AS $250.00 02/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444863
Principal investigator 1 Novo Nordisk AS $350.00 02/07/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444865
Principal investigator 1 Allergan Inc. $4,004.25 02/05/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021257
Principal investigator 1 Novo Nordisk AS $8,451.12 01/24/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
NN1250-4252 No dispute reported 06/30/2026 692444861
Principal investigator 1 Allergan Inc. $11,894.95 01/03/2019 Non-covered Recipient Entity
RESEARCH TRIALS WORLDWIDE LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014505